Tavo Biotherapeutics Strengthens Leadership Team with New Executive Appointments

Introduction

Tavo Biotherapeutics, recognized as a leader in the ophthalmology sector, has unveiled significant additions to its executive team. This strategic move is aimed at enhancing the company’s ability to address critical unmet medical needs in glaucoma and retinal diseases. The appointments of Lukas Scheibler, Ph.D., as Chief Research and Development Officer, and Graham Cooper as Chief Financial Officer, mark a pivotal moment in Tavo's growth trajectory.

New Executive Profiles

Dr. Lukas Scheibler

Dr. Scheibler brings a wealth of experience and expertise to his role as Chief Research and Development Officer. He is highly regarded in the ophthalmology field, having held prominent positions at major firms. Prior to joining Tavo, Dr. Scheibler was Chief Innovation Officer at Apellis, overseeing all R&D activities up to human proof of concept. He has an impressive track record, including contributions to the successful introduction of Lucentis in Europe while working at Novartis, and leading clinical development initiatives at Alcon. His academic credentials include a Ph.D. from the University of Lausanne and postdoctoral training at Harvard Medical School, positioning him as a central figure in driving Tavo's clinical and pre-clinical programs focused on glaucoma and retinal diseases.

Graham Cooper

Graham Cooper joins Tavo as Chief Financial Officer, bringing over two decades of extensive experience in the biotechnology industry. Prior to joining Tavo, he played a vital role as CFO at Receptos, where he was instrumental during its transition through a significant growth phase which culminated in its acquisition by Celgene for a remarkable $7.8 billion. His background includes positions at several biotechnology enterprises, where he developed innovative antiviral therapies and successfully managed capital raises exceeding one billion dollars. Additionally, Mr. Cooper’s previous experience at Deutsche Bank Securities and Deloitte Touche underscores his robust financial acumen and network in the venture capital and public investor communities.

The Vision for Tavo Biotherapeutics

Gary Berman, Tavo’s CEO, expressed enthusiasm over the new appointments, emphasizing the timing as critical for the firm’s current objectives. “Lukas and Graham fill pivotal roles for Tavo, and they join us at a key time as we prepare to raise capital and advance our pipeline into the clinic,” Berman stated. Their combined leadership is expected to be a driving force behind the development of breakthrough therapies targeting fundamental needs in ophthalmology.

Innovative Pipeline

Tavo Biotherapeutics has made significant strides in developing therapies aimed at critical unmet needs in the ophthalmic space. Their flagship drug, TAV-001, is targeting glaucoma-related neurodegeneration. Early pre-clinical studies have demonstrated its potential to substantially reduce intraocular pressure while presenting intriguing indicators of neuroprotection. This positions TAV-001 as a possible first disease-modifying treatment for glaucoma patients, with expectations set for entering Phase 1 clinical trials in 2025.

Additionally, TAV-002 is in the pipeline as a prospective first-in-class treatment for various retinal diseases, including diabetic macular edema and diabetic retinopathy, as well as age-related macular degeneration. The company has already initiated activities to support Investigational New Drug (IND) applications for this program.

Conclusion

The additions of Dr. Lukas Scheibler and Graham Cooper to Tavo Biotherapeutics' executive team signify the company’s commitment to innovation and improving treatment options for patients facing critical challenges in ophthalmology. As Tavo continues its work towards groundbreaking therapies, the industry watches keenly, anticipating the developments that will arise from this strengthened leadership.

For more information about Tavo Biotherapeutics and its innovative pipeline, visit www.tavobio.com.